Sugi Predict

Sugi Predict / Compounds / SCHEMBL826321

SCHEMBL826321

SCHEMBL826321

Cc1cccc(OCCCC(=O)O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.65
▸ KMT2A Q03164 3/20 0.61
▸ HPGD P15428 2/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ TSHR P16473 1/20 0.59
▸ LMNA P02545 2/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ FFAR4 Q5NUL3 1/20 0.59
▸ GAA P10253 1/20 0.59
▸ MAPK1 P28482 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ DRD2 P14416 1/20 0.56
▸ DRD4 P21917 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8278944 0.95 KMT2A (0.60) SMN1; SMN2KMT2AHPGDMEN1TSHR
SCHEMBL20230314 0.94 PPARA (0.59) SMN1; SMN2KMT2AHPGDMEN1TSHR
SCHEMBL8357771 0.94 PPARA (0.59) SMN1; SMN2KMT2AHPGDMEN1TSHR
SCHEMBL10102862 0.94 PPARA (0.59) SMN1; SMN2KMT2AHPGDMEN1TSHR
SCHEMBL13450150 0.94 PPARA (0.59) SMN1; SMN2KMT2AHPGDMEN1TSHR
SCHEMBL2777259 0.92 L3MBTL1 (0.64) SMN1; SMN2KMT2AHPGDMEN1LMNA
SCHEMBL31302989 0.92 L3MBTL1 (0.64) SMN1; SMN2KMT2AHPGDMEN1LMNA
Hydrochloric Acid SCHEMBL2777750 0.90 L3MBTL1 (0.62) SMN1; SMN2KMT2AHPGDMEN1LMNA
SCHEMBL13523837 0.87 SMN1; SMN2 (0.65) SMN1; SMN2KMT2AHPGDMEN1LMNA
SCHEMBL6850974 0.87 SMN1; SMN2 (0.65) SMN1; SMN2KMT2AHPGDMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260071218-A1 Oral Delivery of Antisense Conjugates Targeting PCSK9 CIVI BIOPHARMA INC (US) 2026-03-12 — — US claimed
US-20240067965-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA INC (US) 2024-02-29 — — US claimed
EP-4259799-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 Civi Biopharma, Inc. (US) 2023-10-18 — — EP claimed
CN-116897206-A Oral delivery of PCSK 9-targeting antisense conjugates 四纬生物制药股份有限公司 2023-10-17 — — CN claimed
WO-2022125913-A9 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA, INC. (US) 2023-06-08 — — WO claimed
US-20220213476-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA, INC. (US) 2022-07-07 — — US claimed
WO-2022125913-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA, INC. (US) 2022-06-16 — — WO claimed
EP-2579868-B1 ORAL IRON DEFICIENCY THERAPY EMISPHERE TECH INC (US) 2018-03-07 — — EP claimed
US-9402864-B2 Oral iron deficiency therapy EMISPHERE TECHNOLOGIES, INC. (US) 2016-08-02 — — US claimed
US-20130230604-A1 ORAL IRON DEFICIENCY THERAPY Emispere Technologies, Inc. (US) 2013-09-05 — — US claimed
EP-2579868-A2 ORAL IRON DEFICIENCY THERAPY Emisphere Technologies, Inc. (US) 2013-04-17 — — EP claimed
WO-2011156563-A2 ORAL IRON DEFICIENCY THERAPY EMISPHERE TECHNOLOGIES, INC. (US) 2011-12-15 — — WO claimed
US-20260071218-A1 Oral Delivery of Antisense Conjugates Targeting PCSK9 CIVI BIOPHARMA INC (US) 2026-03-12 — — US disclosed
US-12291708-B2 Oral delivery of antisense conjugates targeting PCSK9 CIVI BIOPHARMA, INC. (US) 2025-05-06 — — US disclosed
US-20240207409-A1 ORAL DELIVERY OF OLIGONUCLEOTIDES CIVI BIOPHARMA INC (US) 2024-06-27 — — US disclosed
US-12018019-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2024-06-25 — — US disclosed
WO-2008014430-A1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-01-31 — — WO disclosed
US-7196080-B2 Respiratory system disordeers; chronic obstructive pulminary disease ASTELLAS PHARMA INC. (JP) 2007-03-27 — — US disclosed
WO-2007000550-A2 NOVEL INDOLINE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-01-04 — — WO disclosed
JP-2000136188-A ANTITHROMBOTIC SUBSTANCE ELI LILLY & CO 2000-05-16 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071218-A1 Oral Delivery of Antisense Conjugates Targeting PCSK9 PCSK9, ALPI, SLC10A2 SMN1; SMN2 601/4885KMT2A 1618/4885HPGD 4523/4885
US-12018019-B2 Estrogen receptor-modulating compounds ESR2, GPER1, ESR1 SMN1; SMN2 4743/4885KMT2A 3309/4885HPGD 510/4885
US-20240207409-A1 ORAL DELIVERY OF OLIGONUCLEOTIDES RNGTT, RNMT, SRRT SMN1; SMN2 2831/4885KMT2A 3729/4885HPGD 4651/4885
US-20240067965-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 PCSK9, SCD5, PCSK7 SMN1; SMN2 1198/4885KMT2A 1786/4885HPGD 4154/4885
US-20220213476-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 PCSK9, SCD5, PCSK7 SMN1; SMN2 1198/4885KMT2A 1786/4885HPGD 4154/4885
US-12291708-B2 Oral delivery of antisense conjugates targeting PCSK9 PCSK9, SCD5, PCSK7 SMN1; SMN2 1198/4885KMT2A 1786/4885HPGD 4154/4885
US-20130230604-A1 ORAL IRON DEFICIENCY THERAPY SLC40A1, FECH, HAMP SMN1; SMN2 2766/4885KMT2A 2480/4885HPGD 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.